March 2006 Issue - Endovascular Today

Table of Contents

Issue

March 2006

In This Issue

Innovations

James Joye, DO

Dr. James Joye, inventor of cryoplasty, discusses his experiences developing the procedure, bias in medicine, and the latest initiatives of VIVA Physicians.

By James Joye, DO

Conference Coverage

Highlights From ISET

Nonstent Endovascular Treatment of SFA Occlusions

High failure rates of balloon angioplasty and stent fracture suggest a need for nonstent alternatives.

By Robert S. Dieter, MD, RVT, and John R. Laird, Jr, MD

Direct Tibial Artery Access: A New Approach to Challenging CTOs

When conventional femoral access did not permit antegrade guidewire traversal, successful retrograde guidewire traversal was achieved in four cases using direct tibial artery puncture.

By Shaddy K. Younan, MD, and David E. Cohen, MD

Cover Story

Crossing Peripheral CTOs

A look at today's options, from guidewires to re-entry devices.

By Tony Das, MD

Successful CTO Recanalization

A case-based review of new tools and techniques.

By James Joye, DO

When Is Surgery Still the Best Option?

Given the variety of endovascular treatment modalities for lower-leg interventions, when should physicians consider surgical treatment in their patient management?

By Panagiotis Kougias, MD; Wei Zhou, MD; Alan B. Lumsden, MD; and Peter H. Lin, MD

Creative Access Techniques for CTOs

New technology and unconventional approaches help to maximize success in difficult cases.

By Charles F. Botti, Jr, MD, and Gary M. Ansel, MD

Thrombolytic Therapy for Peripheral CTOs

The role of this therapy has expanded, allowing for successful treatment of more patient groups.

By Amir Motarjeme, MD

Departments

MR Safety of Cardiovascular Implants

New standards are being developed to ensure patient safety during procedures involving magnetic resonance imaging.

By Terry O. Woods, PhD

CTO Device Update

Industry Perspective

An Overview of the CTO Device Market

As the number of lower-limb PAD treatments increases, the market for CTO crossing aids to permit these treatments will develop, driving this market to $355 million by 2011.

By Kamran Zamanian, PhD

Up Front

Chronic Total Occlusions

By John R. Laird, Jr, MD Chief Medical Editor

Varicose Vein Update

Options for Treating the Saphenous Vein

A discussion of radiofrequency versus laser versus chemical ablation.

By Jose I. Almeida, MD, FACS, RVT, and Jeffrey K. Raines, PhD, RVT

Saphenous Vein Ablation

Do different laser wavelengths translate into different patient experiences?

By Edward G. Mackay, MD; Jose I. Almeida, MD; and Jeffrey K. Raines, PhD

Endovenous Ablation Device Chart